

XX
 PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
 XX
 DR WPI; 2000-638211/61.
 XX
 N-PSDB; AAC59829.

XX
 Novel proteins and polypeptides useful for the treatment of e.g.
 PT multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis,
 PT cancer, Alzheimer's disease, Parkinson's disease, stroke, anemia and
 PT ulcers

XX
 PS Claim 92; Page 441-442; 49pp; English.

XX
 CC This invention relates to 59 human secreted proteins and the nucleotide
 sequences encoding them. Sequences AAC59788-59846 and AAB34687-34745
 represent the proteins and their encoding nucleotide sequences, and
 sequences AAB3446-B34771 represent fragments of the proteins. Probes
 CC for the DNA sequences are represented by sequences AAC59847-C5956. The
 CC proteins exhibit neuroprotective, dermatological, immunosuppressive,
 antiinflammatory, antianoxic, nootropic, antiparkinsonian,
 cerebroprotective, haemostatic, vulnerary, cytoprotective,
 antibacterial, virucide, and fungicide activity. The proteins and
 nucleotide sequences are useful as nutritional sources or supplements
 CC and in research. The proteins are useful for treating immune deficiencies
 and disorders, which may be genetic or resulting from infections,
 autoimmune disorders such as multiple sclerosis, systemic lupus
 erythematosus, rheumatoid arthritis, and for treating myeloid or lymphoid
 CC cell deficiencies such as anaemias by regulating haematopoiesis. The
 CC proteins are also useful in compositions for bone, cartilage, tendon,
 ligament and/or nerve tissue growth or regeneration, for wound healing,
 CC tissue repair and replacement and in the treatment of wounds, incisions
 and ulcers. Other uses include in the treatment of central and
 peripheral nervous system and neuropathies such as Alzheimer's and
 parkinson's diseases and Shy-Drager syndrome, and mechanical and
 CC traumatic disorders, such as spinal cord disorders, head trauma and
 stroke. The proteins may also be used as a contraceptive, and for
 CC treating coagulation disorders such as haemophilia. The protein and
 nucleotide sequences with cadherin activity are useful for treating
 CC cancer. Other uses for the protein include for inhibiting the growth,
 infection or function of, or killing, infectious agents such as bacteria,
 CC virus, fungi and other parasites, for effecting bodily characteristics
 such as height, weight, hair colour, effecting biorhythms or cardiac
 CC cycles or rhythms, effecting metabolism, catabolism, anabolism,
 protein processing, utilization, storage or elimination of dietary fat, lipid,
 CC protein, carbohydrate, vitamins, minerals, cofactors, effecting
 behavioural characteristics, providing analgesic effects
 CC hyperproliferative disorders such as psoriasis.

XX
 SQ Sequence 119 AA:

Query Match 100.0%; Score 644; DB 21; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.7e-66; Mismatches 0; Indels 0; Gaps 0;

Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKVLISLLLPLMLMSWSSSLNPGVARGHRDRGQASRRMQLQEGQECBCKDWFLRAP 60
 Db 1 MKVLISLLLPLMLMSWSSSLNPGVARGHRDRGQASRRMQLQEGQECBCKDWFLRAP 60

Oy 61 RKKFMTVSGLPKKQCPDHFKGNVKRQRHRRKPKNSRACQQELKQCOLRSFALPL 119

Db 61 RKKFMTVSGLPKKQCPDHFKGNVKRQRHRRKPKNSRACQQELKQCOLRSFALPL 119

RESULT 2
 AAY82453 standard; Protein: 119 AA.

XX
 AC AAY82453;
 XX
 DT 30-JUN-2000 (first entry)

XX
 Human TGC-440 secretory protein SEQ ID NO:1.

KW TGC-440; secretory protein; immunological disease; infectious disease;
 KW pulmonary function disorder; hepatic function disorder; nephrotoxic;
 KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;
 KW virucide; hepatotoxic; antiasthmatic; antibiotic; vaccine;
 KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
 KW pneumonia; Helicobacter pylori infection.

XX
 OS Homo sapiens.

PN WO200014226-A1.

XX
 PD 15-MAR-2000.

XX
 PF 02-SEP-1999; 99WO-JP04765.

XX
 PR 03-SEP-1998; 98JP-0250108.

XX
 PA (TAKE) TAKEDA CHEM IND LTD.

XX
 Itoh Y, Ogi K, Tanaka H, Kitada C;

XX
 DR WPI; 2000-256978/22.

XX
 DR N-PSDB; AAA08343, AAA08344.

XX
 PS Claim 1; Fig 1; 86pp; Japanese.

The present sequence represents a human secretory protein designated
 TGC-440. TGC-440 has antiinflammatory, hepatotoxic, immunomodulatory,
 CC and can be used in vaccines. TGC-440 and the polynucleotide sequence
 encoding it can be used to treat, prevent, and diagnose immunological,
 CC lung, liver, kidney or gastrointestinal disorders and infectious
 CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
 CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
 CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
 CC specimen.

XX
 SQ Sequence 119 AA:

Query Match 100.0%; Score 644; DB 21; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.7e-66; Mismatches 0; Indels 0; Gaps 0;

Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKVLISLLLPLMLMSWSSSLNPGVARGHRDRGQASRRMQLQEGQECBCKDWFLRAP 60

Db 1 MKVLISLLLPLMLMSWSSSLNPGVARGHRDRGQASRRMQLQEGQECBCKDWFLRAP 60

Oy 61 RKKFMTVSGLPKKQCPDHFKGNVKRQRHRRKPKNSRACQQELKQCOLRSFALPL 119

Db 61 RKKFMTVSGLPKKQCPDHFKGNVKRQRHRRKPKNSRACQQELKQCOLRSFALPL 119

RESULT 3
 AAY87317 standard; Protein: 119 AA.

XX
 AC AAY87317;

XX
 DT 11-MAY-2000 (first entry)

XX
 DE Human signal peptide containing protein HSPP-94 SEQ ID NO:94.

XX
 KW Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
 KW antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotoxic;
 KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
 KW reproductive disorder; developmental disorder; arteriosclerosis;
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;

KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
 KW Parkinson's disease; Huntington's diseases; ovulatory defect;
 KW muscular dystrophy.
 XX
 OS Homo sapiens.
 XX
 PN WO200000610-A2.
 XX
 PD 06-JAN-2000.
 XX
 PF 25-JUN-1999; 99WO-US14484.
 XX
 PR 26-JUN-1998; 98US-0090762.
 PR 31-JUL-1998; 98US-0094983.
 PR 01-OCT-1998; 98US-0102689.
 PR 11-DEC-1998; 98US-0112129.
 XX
 PA (INCY-) INCYTE PHARM. INC.
 XX
 Ial P, Tang YT, Gorjone GA, Corley NC, Guequier KJ, Baughn MR;
 PI Averbloom IE, Au-Yong J, Yue H, Patterson C, Reddy R, Hillman JL;
 PI Bandman O;
 XX
 DR WI; 2000-160673/14.
 DR N-PSDB; AA298202.
 XX
 PT New human signal Peptide-containing Proteins useful in treatment,
 prevention and diagnosis of e.g. cancer, inflammation and
 cardiovascular disease
 XX
 PS Claim 1; Page 220-221; 327pp; English.
 XX
 AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the
 human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
 anticancer, anti-inflammatory, antimicrobial, nontropic, hepatotropic,
 neuroprotective, cardiovascular, and antiasthmatic activities, and can
 be used in gene therapy. HSPPs can be used to treat or prevent disorders
 associated with decreased activity or function of HSPP. Antagonists of
 HSPP are used to treat or prevent disorders associated with increased
 activity or function of HSPP. Such diseases include cell proliferation
 (including cancer), inflammation, cardiovascular, neurological,
 reproductive or developmental disorders, (e.g. arteriosclerosis,
 cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
 asthma, Crohn's disease, microbial or other infections, congestive or
 ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
 diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
 nucleic acids can be used for the recombinant production of HSPP, for
 detecting HSPP in standard hybridisation and amplification assays (for
 diagnosis and monitoring), in gene therapy, as antisense,
 triplex-forming or ribozyme therapeutics, for detecting related sequences
 or genetic variations, and for chromosomal mapping. HSPP are also used to
 raise specific antibodies (Ab) and to screen for agonists and
 antagonists (potential therapeutic agents). Ab are used to diagnose, or
 monitor HSPP-related diseases (in usual immunoassays), as therapeutic
 antagonists, in competitive drug screens, and for purification of HSPP
 from natural sources.
 XX
 SQ Sequence 119 AA:
 Query Match 100.0%; Score 644; DB 21; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;
 matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 MKYLISSKULLPLMLMNSVSSLNPGVARGHEDRGASRRWQEGSBECEKDWFELRAP 60
 Db 1 MKYLISSKULLPLMLMNSVSSLNPGVARGHEDRGASRRWQEGSBECEKDWFELRAP 60
 61 RRKFMVSLPKQCPDFKGKVKKTRQRHRPKNSRACQQFLKQCOLRSFALP 119
 Db 61 RRKFMVSLPKQCPDFKGKVKKTRQRHRPKNSRACQQFLKQCOLRSFALP 119
 PR 19-JUN-1998; 98US-0089947.
 PR 19-JUN-1998; 98US-0089948.
 PR 19-JUN-1998; 98US-0089952.
 PR 18-JUN-1998; 98US-0089801.
 PR 18-JUN-1998; 98US-0089907.
 PR 18-JUN-1998; 98US-0089908.
 PR 17-JUN-1998; 98US-0089538.
 PR 17-JUN-1998; 98US-0089514.
 PR 16-JUN-1998; 98US-0089440.
 PR 16-JUN-1998; 98US-0089512.
 PR 17-JUN-1998; 98US-0089532.
 PR 17-JUN-1998; 98US-0089538.
 PR 17-JUN-1998; 98US-0089598.
 PR 17-JUN-1998; 98US-0089600.
 PR 17-JUN-1998; 98US-0089653.
 PR 18-JUN-1998; 98US-0089907.
 PR 18-JUN-1998; 98US-0089908.
 PR 22-JUN-1998; 98US-0090246.
 PR 22-JUN-1998; 98US-0090252.
 PR 22-JUN-1998; 98US-0090254.
 PR 23-JUN-1998; 98US-0090349.

CC chromosomal and gene mapping, and in the generation of anti-sense RNA and DNA. They may also be used to produce transgenic animals which are used to develop and screen therapeutically useful reagents. The PRO nucleotide and protein sequence can be used for tissue typing and in treating cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF4270 to AAF4470 represent PCR primers and hybridization probes used in the isolation of human PRO sequences. AAF4087 to AAF4269 and CC sequences given in the exemplification of the present invention.

CC sequence 119 AA; SQ sequence 119 AA;

Query Match 100.0%; Score 644; DB 22; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.7e-66; Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLILLPLPMMSMSSSLPVGAVGSRHRDGQSARWLGQEGCQECKDWFLRAP 60
 Db 1 MKVLISLILLPLPMMSMSSSLPVGAVGSRHRDGQSARWLGQEGCQECKDWFLRAP 60

QY 61 RRKFMVSGLKKQCPDCDHFKGNVKTRQRHRRPKNSRACQQFLKQCOLSFALPL 119
 Db 61 RRKFMVSGLKKQCPDCDHFKGNVKTRQRHRRPKNSRACQQFLKQCOLSFALPL 119

RESULT 9
 AAY82454
 ID AAY82454 standard; Protein: 97 AA.
 XX
 AC AAY82454;
 XX DT 30-JUN-2000 (first entry)
 XX Mature human TGC-440 secretory protein SEQ ID NO:7.
 XX KW TGC-440; secretory protein; immunological disease; infectious disease; pulmonary function disorder; hepatic function disorder; nephrotropic; gastrointestinal function disorder; antiinflammatory; immunomodulatory; KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine; hepatitis; nephritis; influenza; asthma; pulmonary hypertension; pneumonia; Helicobacter pylori infection.
 XX OS Homo sapiens.
 XX PN WO200014226-A1.
 XX PD 16-MAR-2000.
 XX PR 02-SEP-1999; 99WO-JP04765.
 XX PR 03-SEP-1998; 98JP-0250108.
 XX PR (TAKE) TAKEDA CHEM IND LTD.
 XX PI Itoh Y, Ogi K, Tanaka H, Kitada C;
 XX DR WPI: 2000-256972/22.
 XX DR N-PSDB; AAK08345.

PT Secretory protein TGC440, antibodies to it and compounds promoting or inhibiting its activity for diagnosis and treatment of diseases of the immune system, lung, kidney, liver, and intestinal system - Disclosure: Page 80; 86pp; Japanese.
 XX CC the present sequence represents the mature human secretory protein TGC-440. TGC-440 has antinflammatory, nephrotropic, immunomodulatory, virucide, hepatotropic, antisthmatic and antibacterial activities, and can be used in vaccines. TGC-440 and the polynucleotide sequence encoding it can be used to treat, prevent and diagnose immunological, lung, liver, kidney or gastrointestinal disorders and infectious diseases such as hepatitis, nephritis, influenza, asthma, pneumonia, pulmonary hypertension, and Helicobacter pylori infection. An antibody

CC immunospecific for TGC-440 is also useful in the above treatment and diagnosis, and also for quantifying the amount of TGC-440 in a liquid specimen.
 CC Sequence 97 AA;
 Query Match 85.1%; Score 548; DB 21; Length 97;
 Best Local Similarity 100.0%; Pred. No. 1.6e-55; Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 23 SLPNGVARGHIDRGQSARWLGQEGCQECKDWFLRAPRKFMTVSGLPRKQCPDCDHFKG 82
 Db 1 SLPNGVARGHIDRGQSARWLGQEGCQECKDWFLRAPRKFMTVSGLPRKQCPDCDHFKG 60
 QY 83 NVKKTRHQRHRRPKNSRACQQFLKQCOLSFALPL 119
 Db 61 NVKKTRHQRHRRPKNSRACQQFLKQCOLSFALPL 97

RESULT 10
 AAW83953
 ID AAW83953 standard; Protein: 93 AA.
 XX AC AAW83953;
 XX DT 28-JAN-1999 (first entry)
 XX DE Polypeptide encoded by gene 7 clone RJPBD64.
 XX KW Secreted protein; gene therapy; protein therapy; diagnosis; treatment; central nervous system; CNS; immune system; cancer; trauma; liver; reproductive disorder; congenital malformation; degenerative disease; inflammatory disease; neoplasia; metabolic disorder; testis; placenta; brain; T cell; spleen; lung; heart; rhabdomyosarcoma; endocrine system; endocrinopathy; endocrine polyglandular syndrome; endocrinoma; sepsis; endocrinopathy; osteoclastoma; bacterial infection; bone.
 XX OS Homo sapiens.
 XX PN WO9845712-R2.
 XX PD 15-OCT-1998.
 XX PR 07-APR-1998; 98WO-US06801.
 XX PR 30-MAY-1997; 97US-0048184.
 PR 08-APR-1997; 97US-0042126.
 PR 08-APR-1997; 97US-0042127.
 PR 08-APR-1997; 97US-0042128.
 PR 08-APR-1997; 97US-0042154.
 PR 08-APR-1997; 97US-0042125.
 PR 30-MAY-1997; 97US-0048168.
 PR 30-MAY-1997; 97US-0048070.

XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX PI Feng P, Ni J, Rosen CA, Ruben SM, Yu G;
 XX DR WPI: 1998-594496/50.
 XX PT New isolated human genes and secreted polypeptides) they encode -
 PT useful for the diagnosis and treatment of e.g. cancers, CNS disorders, immune system disorders, inflammatory disease and bacterial infections
 XX PS Disclosure: Page 10; 142pp; English. **SEARCH ID NO: 53 (P126)**
 XX CC This represents a polypeptide encoded by the nucleic acid molecule CC designated Gene 7 from the human cDNA clone RJPBD64 (deposited CC as clone ATCC 97955 and ATCC 200974) which encodes a human secreted protein of the invention. The gene is expressed primarily in liver, spleen, bone marrow and to a lesser extent in amygdala and is useful as CC reagents for differential identification of tissues in a biological

The invention relates to 20 novel genes and their fragments (AAW96911 to AAW96950) and corresponding secreted proteins (AAW83911 to AAW83950) which are useful for preventing, treating or ameliorating medical conditions e.g. by protein or gene therapy. Also pathological conditions can be diagnosed by determining the amount of the new polypeptides in a sample or by determining the presence of mutations in the poly nucleotides. Specific uses are based on which tissues they are most highly expressed in, and include developing products for the diagnosis or treatment of central nervous system (CNS) and immune system diseases, reproductive disorders, cancers, congenital malformations, degenerative diseases, trauma, inflammatory disease, neoplasia, metabolic disorders, diseases in testes, placenta, liver, brain and activated T cells, spleen, lung diseases, heart diseases, rhabdomyosarcoma and disorders of the endocrine system or other endocrinopathies, e.g. endocrine polyglandular syndrome, endocrinoma, and endocrine ophthalmopathy, osteoclastoma and other bone remodeling disorders, bacterial infections and sepsis. The polypeptides are also useful for identifying their binding partners.

XX
XX SQ Sequence 93 AA:

Query	Match	Score	DB	Length
Best	Local Similarity	81.8%	19;	93;
Matches	100.0%		Pred. No.	4.2E-53;
93;	Conservative	0;	Mismatches	0;
AC			Indices	0;
XX			Gaps	0
AY82457;				
AC				
XX				
DT	30-JUN-2000 (first entry)			
XX				
DE	Mouse TGC-440 secretory protein SEQ ID NO:3.			
XX	TGC-440; secretory protein; immunological disease; infectious disease; pulmonary function disorder; hepatic function disorder; nephrotropic; gastrointestinal function disorder; antiinflammatory; immunomodulatory; virucide; hepatotropic; antiasthmatic; antibacterial; vaccine; hepatitis; nephritis; influenza; asthma; pulmonary hypertension; pneumonia; Helicobacter pylori infection.			
XX	Mus sp.			
XX				
PN	W020014226-A1.			
XX				
PD	16-MAR-2000.			
XX				
PF	02-SEP-1999; 99WO-JP04765.			
XX				
PR	03-SEP-1998; 98JP-0250108.			
XX				
PA	(TAKE) TAKEDA CHEM IND LTD.			
XX				
PI	Itoh Y, Ogi K, Tanaka H, Kitada C;			
XX				
DR	WPI; 2000-256978/22.			
XX				
PR	N-PSDB; AIA08349, AAA08350.			
XX				
PR	Secretory Protein TGC440, antibodies to it and compounds promoting or inhibiting its activity for diagnosis and treatment of diseases of the immune system, lung, kidney, liver and intestinal system			
XX				